Clinical Trial Update: Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) [Phase 2]

View source ↗

Summary

Phase 2a dose-ranging study of PF-05221304 in nonalcoholic fatty liver disease/nonalcoholic steatohepatitis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• PF-05221304

Snippet

Sponsor: Pfizer | Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2020-03-10